Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wai Chun Bio-Technology Ltd. ( (HK:0660) ) has shared an announcement.
Wai Chun Bio-Technology Ltd. held its Annual General Meeting (AGM) on March 19, 2025, where all proposed resolutions were voted on by poll. The resolutions included re-electing Mr. He Tao as an independent non-executive director, re-appointing McMillan Woods (Hong Kong) CPA Limited as the company’s auditor, and granting mandates to the directors to issue and repurchase shares. Notably, the resolutions to grant general mandates for issuing and repurchasing shares were overwhelmingly voted against, indicating potential concerns from shareholders about these actions.
More about Wai Chun Bio-Technology Ltd.
Wai Chun Bio-Technology Ltd. is a company incorporated in the Cayman Islands, operating in the biotechnology industry. The company is listed on the Hong Kong Stock Exchange and focuses on developing and providing biotechnological products and services.
YTD Price Performance: 50.0%
Average Trading Volume: 179,760
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$18.01M
For an in-depth examination of 0660 stock, go to TipRanks’ Stock Analysis page.